Home /
Insights /
Will Life Sciences Companies Face More Scrutiny in 2018?

Will Life Sciences Companies Face More Scrutiny in 2018?

January 9, 2018

Law360

Partners John Bentivoglio and Jennifer Bragg look at key enforcement trends for life sciences companies from 2017 and discuss what to expect in the year ahead.

Stay Connected

@SkaddenArps

August 8 SEC Proposes to Ease Disclosures Required by Rules 3-10 and 3-16 of Regulation S-X in Certain Registered Debt Offer… twitter.com/i/web/status/1…
August 8 MSRB Notes Compliance Risks of Issuer-Solicited Charitable Donations skadden.com/insights/publi…
August 8 Montana Enacts New Pay-to-Play Disclosure Requirements skadden.com/insights/publi…